Uscom Limited
Annual Report 2018

Plain-text annual report

Annual Report 2018 www.uscom.com.au Uscom 2018 Annual ReportCONTENTS CHAIRMAN’S LETTER ................................................................................................................ 2-7 ANNOUNCEMENTS FY 2018 ............................................................................................... 8 DIRECTORS REPORT ....................................................................................................... 9-15 FINANCIAL REPORT AUDITORS INDEPENDENCE DECLARATION ....................................................................... 16 STATEMENT OF PROFIT AND LOSS & OTHER COMPREHENSIVE INCOME ................... 17 STATEMENT OF FINANCIAL POSITION ................................................................................ 18 STATEMENT OF CHANGES IN EQUITY ................................................................................. 19 STATEMENT OF CASH FLOWS .............................................................................................. 20 NOTES TO FINANCIAL STATEMENTS .............................................................................. 21-41 DIRECTORS DECLARATION .............................................................................................. 42 INDEPENDENT AUDIT REPORT ................................................................................... 43-45 SHAREHOLDER INFORMATION ................................................................................... 46-47 CHAIRMAN’S LETTER DEAR INVESTORS, CUSTOMERS, PARTNERS, AND EMPLOYEES: “Founding a global company, acquiring two others, developing ten sector leading cardiovascular and pulmonary products, establishing global manufacturing, sales, marketing and distribution, and educating clinicians on how these technologies save patient’s lives has taken longer and cost more than we thought. However, the opportunity is much greater than we ever anticipated For Uscom shareholders 2018 was a year of expansion in preparation for the growth associated with the release of our new products. This involved investment in expanded manufacturing and distribution, and ensuring we have the manufacturing capacity to meet the anticipated demand as we launch our new products across four continents. ANNUAL REPORT 2018 | Uscom Limited | Page 2 MILESTONES Cornerstone Chinese investor in Uscom Limited Uscom China established and Beijing office opened Appointment of Uscom Director of China Operations, Ms Teresa Guo New and expanded Australian head office and manufacturing facility New appointment VP North American Sales, Mr Curt Grosse Investment in seven new products and regulatory BP+ released and CE certified BP+ and SpiroSonic in CFDA and FDA regulatory approval cycle SpiroReporter and BP+ Reporter released New Sales, Marketing and Distribution division for Europe RESULTS Total income - $2.86M (down 18%) Cash on hand – $2.49M (up 50%) Total shareholder equity - $4.84M (up 28%) Cash consumption - $1.70M R&D, regulatory & other non-recurring costs - $1.50M 5 year growth in annual cash receipts – 27% per year 6 year growth in annual revenue – 22% per year China: China activities were expanded in 2018 with the establishment of Uscom China, the appointment of an outstanding Director of China Operations and the opening of our Beijing office. Success in China “is all dependent on obtaining import permits from Chinese regulators and a sound strategy to access the lucrative market.” Uscom now has strong China partners with experience in regulatory and IP management, and a clear strategy to access the expanding China healthcare market. This pathway and the infra structure we are building in China will become a conduit for new products for years to come. This strategic focus was led by the investment of a cornerstone international, Beijing based bio-investor who acquired more than 17% of Uscom’s issued capital. China remains the fastest growing world market for medical devices, and Uscom is invested in China. Europe: Uscom Budapest is being expanded to become a centre of European operations, to include sales for USCOM 1A and BP+ devices as well as SpiroSonic devices. Uscom Kft, as it will be known, will now provide regional technical and customer support and device manufacturing, and will continue with high quality R&D and product development for Uscom global operations. USA: Uscom also expanded its US footprint in FY 2018 and appointed a Vice President of North American Sales – Curt Grosse, with a brief to grow USCOM 1A sales, and prepare the market for BP+ and SpiroSonic sales following FDA certification. Products: We continued to drive the regulatory certification processes in China, Europe and the US for all our products. This process is complex and somewhat unpredictable, but all devices are now in the approval phase. The commercial opportunity of this multi- product, multi-jurisdictional global network will be defined as we transition the newly certified products to distribution, sales, revenue and profit. (Graph 1) Uscom remains focused on bringing world leading cardiovascular and pulmonary medical devices to global markets to improve clinical care. Uscom’s investment in growth, is increasing shareholder value as we drive toward profitable global operations and dividends. ANNUAL REPORT 2018 | Uscom Limited | Page 3 Total income of $2.86M, decreased 18% on the prior corresponding period (pcp). However growth trends remain strong with total income maintaining a 22% compound annual growth rate (CAGR) for the previous six years, while cash receipts maintained a five year CAGR of 27%. The operating loss after income tax increased 9% to $1.96M, total operating cash consumption for the year was $1.70M, while cash on hand was up 50% to $2.49M, and total shareholder equity increased 28% to $4.84M. Total employee expenses for the global entity were down 24% to $1.71M, including the CEO’s total remuneration which was reduced by 61%. In FY 2018 an experienced, Beijing based, international bio-investor, began taking an equity position in Uscom, and now owns >17% of Uscom’s total equity. The investor brings high level experience in the Chinese market, strong capital contacts, and a personal commitment to growing the Australian entity. The decrease in sales and income for the year was partly due to delays in manufacturing associated with the relocation and expansion of our head office and manufacturing centre, and the accompanying re- accreditation of Uscom’s manufacturing facilities. This relocation and expansion was an essential step to allow transition from small to medium volume manufacturing to meet the anticipated increased USCOM 1A demand from China and the US, and global demand for the new BP+ devices as they receive regulatory certification. There was a further delay as new regulatory approvals, which were necessary prior to resumption of any manufacturing, were processed, resulting in a combined delay in manufacturing and delivery of orders of nearly four months. We also spent approximately $1M developing new concepts, IP and devices, and optimising current devices, much of which will be re- imbursed by R&D grants in FY 2019. Total income from Uscom Europe fell 17% on the pcp ($0.70M to $0.58M). However approximately $250K of contracted Government R&D remains outstanding. Additionally the costs of development of new devices and products by the Budapest team have been met. The vision for Uscom Europe is that it will expand to a sales, marketing, and clinical and technical support hub for all Uscom products in Europe, and retain its R&D function while expanding manufacturing to meet increased demand associated with CFDA and FDA approvals. We have begun recruiting new sales staff and distributors to support the newly released BP+ and BP+ Reporter hypertension solution and the new SpiroSonic devices in Europe. ANNUAL REPORT 2018 | Uscom Limited | Page 4 Non-recurring funding associated with the above activities can be summarised as: 1. Relocation to expanded Sydney manufacturing facility - $200K + 4mths non/delayed manufacture 2. Establishment of Uscom China and opening of Beijing office 3. Budapest special cash funding to comply with requirements of the R&D grants - $120K 4. $845K R&D spend 5. Regulatory application for CFDA and FDA are in the order of $100k, for each application. Share trading: The Uscom FPO VWAP share price in FY 2018 was 21c, ranging from 14.5c to 29c. Importantly liquidity continues to increase, with 23M shares traded for the year up 43% from 16M in the pcp. Importantly the price of a rapidly growing biotechnology company, where assets are often intangible such as patents and regulatory certifications, is difficult for investors to correctly value. We look forward to the substantial investments in new devices, regulatory approvals and marketing and distribution converting to revenue and being more appropriately reflected in the UCM share price over the next 12 months. (Graph 2) Science: Uscom continues to develop and refine practice leading devices for non-invasive cardiovascular and pulmonary monitoring. The USCOM 1A remains the leading cardiac output monitor in clinical and research practice and is deployed to save the lives of children and adults around the world. It is also now being increasingly adopted as a standard of care for pre-eclampsia, the leading cause of maternal and foetal death in pregnancy. The new BP+ and BP+ reporter provide companion technologies that increase the number of parameters to measure hypertension from 3-4 measures in conventional devices, to more than 25 parameters. Additionally the BP+ technology stores and displays three pulse pressure waveforms from the heart, aorta and the arm from a 45 second measure. These measures were only previously provided by cardiac catheters. This additional data provides unique diagnostic and analytic capabilities that can improve the management and understanding of hypertension. The BP+ and BP+ Reporter creates a new clinical benchmark for advanced cardiovascular monitoring and can digitally interface with electronic medical record systems. SpiroSonic devices and the digital interfacing SpiroReporter are also setting standards of pulmonary assessment and being employed in a variety of settings to define and guide improved management in asthma, COPD and occupational lung disease. anticipated to incrementally impact revenue and profitability. Sales, Marketing and Distribution: FY 2018 saw the beginnings of diversification for Uscom, with all three product suites beginning sales and generating early revenues in the three major global markets of China, Europe and the US in multiple currencies. The USCOM 1A provided approximately 75% of all Uscom sales receipts, while SpiroSonic generated 20% and BP+ only 5% from global research sales prior to regulatory approvals in FY 2018. Regionally China and the rest of Asia were responsible for 62% of Uscom sales, while Europe generates 33% and the US 5%. (Graph 3,4) Education and Distributor Support: As part of our new focus on customers, we are expanding our sales, training and education materials so they are standardised for all our products and can then be translated into Chinese. We are also looking to provide increased clinical and technical support with the establishment of Uscom China and the expanded Uscom Budapest role. We will also be looking to establish a new global website and digital sales interface that will be duplicated for Chinese users so global customers can access our products and support. Patents: Patents are important measures of value for biotechnology companies like Uscom, and in FY 2018 Uscom was granted a vital US patent for our unique digital ultrasonic SpiroSonic technology, and a new method of measuring cardiovascular function that is now implemented in the USCOM 1A. These patents provide commercial protection for our specialised and practice leading technology, and reflect a global leadership in cardiovascular science. New Products: Product development and regulatory approval was the priority activity for Uscom in 2018. Below are our achievements: • BP+ and BP+ Reporter development • BP+ and BP+ Reporter CFDA and FDA applications (4 applications each) • BP+ BP+ Reporter CE approval • SpiroSonic and SpiroReporter development (already CE approved) • SpiroSonic and SpiroReporter CFDA and FDA regulatory applications (4 applications each) This process is ongoing and over 2019 we will introduce 7 new products into the 3 major global markets and accessing a market population of 2.5B. Current results are from the sale of 1 product (USCOM 1A) in China, Europe and the US, and sale of our spirometers into Eastern Europe. More products into bigger markets is ANNUAL REPORT 2018 | Uscom Limited | Page 5 Regulatory: The regulatory process is continuing, with all products expected to be certified by the end of FY 2019. Below is the current regulatory status: TGA Aust CE Europe 0.025 0.75 Market Population (B) Uscom 1A BP+ (x2) Yes Yes SpiroSonic (x5) Yes Yes Yes Yes FDA US 0.33 Yes CFDA China 1.40 Yes Submission Submission Submission Submission STRATEGY FY 2019 Management’s objective is to pursue our strategy and drive rapid operational growth off the delivery of multiple products into multiple global markets, as we optimise manufacturing, distribution and sale of our world leading cardiovascular and pulmonary monitoring technologies and establish enduring profitability and dividends for shareholders. The development of Uscom, and the USCOM 1A, followed by the acquisition and integration of the two companies and the development and optimisation of the devices we acquired, has been time consuming and expensive, but in FY 2019 we expect to see the returns on these investments as we deliver eight products into multiple complex market across four continents. The potential for our multi-product company, selling into multiple jurisdictions is outstanding as we anticipate the global revenue opportunities. It is envisaged that in FY 2019 revenue growth will be driven by: 1. Approval of all three product suites and sales of our eight products into multiple markets across four continents 2. Growth of Uscom China 3. Growth of Uscom US and Uscom Europe 4. Global efficiencies of scale, including operations, manufacturing, distribution and sales To achieve this we will continue our focus on the China market, and ensure they have the marketing and sales collateral and product required to support our China distribution partners and support educational symposia. expectations, and may challenge cash flow management and equity adequacy and require focused management. Conclusion FY 2018 was a great year again for Uscom. We continue to grow into a global medical device company with a strong clinical and operational footprint across four continents with a rapidly expanding portfolio of noninvasive cardiovascular and pulmonary medical devices. Most importantly our China activities continue to grow with cornerstone Chinese capital investment, opening of a China office, appointment of a Director of China operations and registration of a wholly owned, Beijing based, China subsidiary, and expanded operations in preparation for the regulatory certification of our new products. We also invested in expanded Australian facilities to meet the anticipated increased manufacturing demand from more products, more territories and more distribution. We initiated the transition of Uscom Budapest into an expanded manufacturing, sales, distribution, technical and customer support centre for all Europe and for all products, as well as preserving its role as an R&D centre. The key to 2019 depends on receiving our regulatory certifications, which are rapidly progressing in China and the US, and the speed with which we can deliver our products into an expanding global distribution. We look forward to investors harvesting the fruits of our investment as we continue to grow. Thank you. Professor Rob Phillips Uscom Chairman While costs are expected to remain high for the coming period as we finalise global regulatory and marketing for our new product series, non-recurring costs should gradually diminish and be replaced by increasing revenue which will drive our transition to profitability. For FY 2019 management have a clear focus on finalising regulatory certification, preparing our manufacturing and distribution infrastructure and expanding sales marketing and distribution resources to drive the growing global demand for all Uscom products. Our focus will be specifically on growing our China operations and developing some of the remarkable opportunities offered by our unique connection to the China market. Risks: Global markets - For Uscom, operating in global markets creates exposure to risk such as international trade wars, US Health reform, US political crisis, Brexit, a China slow down, North Korea and the South China Sea. All of these unpredictable events impacted global markets in 2018 and may evolve to impact our business going forward. While global diversification exposes us to more challenges, it also mitigates us against regional trade and currency risks. China - China is a major market for Uscom and any significant change in marketing terms, including the one or two invoice system, and manufacturing 2025 may influence our China revenue as we adjust our distribution channels. Uscom has confidence in the scale, accessibility and future of the Chinese market. Distributors - Under performance of distributors, particularly where best endeavours contracts are in place, may also impact forecast revenues. Internal monitoring of distributors mitigates such risks by providing regional hands-on distributor management and continual performance monitoring. Regulatory – Regulatory certification is becoming increasingly complex, expensive and time consuming and with increasing uncertainty in all jurisdictions. Uscom is managing the regulatory submissions for eight products across four continents into multiple markets and has already received a number of approvals, and is managing the progress of others. Key personnel - Uscom is dependent on a small and vital team working to ensure and manage on going rapid growth. Implementation of a competitive executive remuneration plan to ensure adequate executive compensation may mitigate the risk of damaging resignations. The establishment of Uscom China and the expansion of the Budapest operations will also mitigate these risks. Other risks - Competitive risks, patent breaches, and scale up stress are potential threats to our growth ANNUAL REPORT 2018 | Uscom Limited | Page 6 Multi-product Income Model UCM Annual Trading Volume 200 150 100 50 0 23 16.1 12.4 5.0 5.2 5.2 4.1 s e r a h s M 25.0 20.0 15.0 10.0 5.0 0.0 2018 2019 2020 2021 2022 2023 2024 2012 2013 2014 2015 2016 2017 2018 USCOM 1A SpiroSonic BP+ (Graph 1) Impact on income of more products, sold by more distributors, into more jurisdictions demonstrating the potential for incremental growth. (Graph 2) Annual trading volume demonstrating a continuous increase in annual shares traded. Product Sales % 2018 Regional Sales 2018 5% 20% 75% 5% 33% 62% USCOM 1A SpiroSonic BP+ China/Asia Europe USA etc. (Graph 3) In FY 2018 the USCOM 1A generated approximately 75% of all Uscom sales receipts, while SpiroSonic generated 20%, and BP+ only 5% from global research sales prior to regulatory approvals. (Graph 4) Regionally China and the rest of Asia are responsible for 62% of all Uscom sales, while Europe generates 33%, and the US 5%. ANNUAL REPORT 2018 | Uscom Limited | Page 7 ASX Announcements are a measure of corporate activity, and below is the list of FY 2018 announcements (Excluding Financial Reporting) with those deemed to be financially sensitive by the ASX marked as ($), being 13 of 25: 1 2 3 4 5 6 7 8 9 21/06/2018 New Uscom Measure of Heart Function ($) 8/06/2018 New Appointment of China Operations Guo 28/05/2018 China and Investor Update May18 24/05/2018 New US IP for Uscom SpiroSonic Devices ($) 10/04/2018 Uscom Asia Investment Non-Deal April 2018-08-01 6/03/2018 BP+ for US eHealth study ($) 28/02/2018 Uscom Investor Update March 2018 12/02/2018 Uscom BP+ Approved by International Hypertension Society 20/12/2017 CE Mark for Uscom BP Plus Sale in Europe 10 19/12/2017 Share placement ($) 11 18/12/2017 International Value Investor Takes Strategic Stake in Uscom ($) 12 15/12/2017 Uscom Receives $492K R&D Cash Refund ($) 13 14/12/2017 Investor Presentation December 2017 14 21/11/2017 New Hypertension Study Recommends Uscom BP+ Measures ($) 15 16/11/2017 Details of Company Address 16 13/11/2017 Uscom receives GSA listing to sell to US Government ($) 17 8/11/2017 Uscom Ltd 2017 AGM Presentation ($) 18 30/10/2017 Uscom BP+ Central Blood Pressure Monitor Released ($) 19 16/10/2017 BP+ and Mount Everest Hypertension Study ($) 20 9/10/2017 USCOM cost effective replacement for ICU Ultrasound ($) 21 21/08/2017 Annual Report to shareholders ($) 22 9/08/2017 New USCOM 1A digital connectivity feature released ($) 23 17/07/2017 Uscom BP+ Distributor for SE Asia ($) 24 13/07/2017 TGA for Uscom SpiroSonic ($) 25 11/07/2017 Euro Funding for Uscom Pulmonary Research ($) ANNUAL REPORT 2018 | Uscom Limited | Page 8 DIRECTOR’S REPORT DIRECTOR’S REPORT The Directors present their report on Uscom Ltd and its Controlled Entities for the financial year ended 30 June 2018. Directors The following persons were Directors of Uscom Ltd during the whole of the financial year and up to the date of this report, unless otherwise stated. Associate Professor R A Phillips Ms S Jack Mr C Bernecker Mr C X He Executive Director - Chairman Non-Executive Director Non-Executive Director Non-Executive Director (Resigned on 23 May 2018) Directors’ qualifications and experience Associate Professor Rob Phillips Rob Phillips is the founder of Uscom Ltd, the Chief Executive Officer, Executive Director and Chief Scientist of the Company. Rob has 14 years’ experience as Executive Chairman of the Company, having taken Uscom to IPO in 2003, and has over 20 years in executive corporate management and capital raising. Rob has overseen the company’s acquisition of two international medical device companies in 2013 and 2016. Rob has a Doctor of Philosophy and a Master of Philosophy in Cardiovascular Medicine from The University of Queensland and is an Adjunct Associate Professor with the Critical Care Research Group, at the School of Medicine, The University of Queensland. He is an Australian Post Graduate Award recipient and was a finalist in the Time-Google-CNN-Science-NYSE World Health and Medicine Technology Awards in 2004. Rob has pioneered novel clinical approaches to cardiovascular assessment having authored over 30 patents and patent applications and is an internationally recognised author, teacher and examiner in the field of cardiac ultrasound, cardiovascular function and circulation. Ms Sheena Jack Ms Sheena Jack is a Non-Executive Director of Uscom Ltd since November 2011. Sheena is the CEO of HCF and has over 25 years’ experience as a finance professional and corporate executive. She has had experience across a range of corporate organisations including ASX listed companies, government and not for profit in both mature and start-up businesses. Sheena has significant experience in mergers and acquisitions, business integration, strategy development and implementation, capital markets and organisational transformation. Sheena is a Chartered Accountant and a graduate member of the Australian Institute of Company Directors. Mr Christian Bernecker Mr Christian Bernecker is a Non-Executive Director of Uscom Ltd since November 2011. Christian is Non-Executive Director of Stream Group Limited and has more than 10 years of broad investment experience across capital raising, acquisitions and divestments. Christian qualified as a Chartered Accountant in Australia and holds a Bachelor of Commerce from Ballarat University. Mr David He Mr David He was a Non-Executive Director of Uscom Ltd since 23 March 2016 and resigned on 23 May 2018. Prior to this appointment, David was the Vice President of Business Development APAC with Johnson & Johnson. Prior to that Mr He was an Associate at McKinsey & Company in Shanghai, then Director of Business Development and External Growth APAC and VP Finance China with AB InBev based in Hong Kong and Shanghai. Company Secretary’s qualifications and experience Mr Brett Crowley Brett Crowley was appointed as the Company Secretary on 24 May 2016. He is a practicing solicitor and a former Partner of Ernst & Young in Hong Kong and Australia, and of KPMG in Hong Kong, and has worked in China establishing and managing JV companies there. Mr Crowley is an experienced chairman, finance director and company secretary of ASX-listed companies, and is a former Senior Legal Member of the NSW Civil and Administrative Tribunal. Meetings of Directors Directors R A Phillips S Jack C Bernecker C X He ANNUAL REPORT 2018 | Uscom Limited | Page 9 Board of Directors Meetings held while a Director 5 5 5 5 No. of meetings attended 5 4 5 1 DIRECTOR’S REPORT Principal activities Uscom Ltd is engaged in the development, design, manufacture and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom Ltd owns a portfolio of intellectual property relating to the technology and techniques associated with these devices and manages a worldwide network of distribution partners for the sale of its equipment to hospitals and other medical care locations. Uscom Ltd owns 100% of Uscom, Inc. a company engaged in the sale and promotion of USCOM devices primarily in the United States, and owns 100% of Thor Laboratories KFT., a company that manufactures respiratory devices based in Hungary. Operating result The loss of the Consolidated Entity after providing for income tax amounted to $1,960,923 (2017: $1,800,849). Dividends No dividends were declared or recommended for the financial year ended 30 June 2018 (2017: nil). Significant changes in state of affairs There were no significant changes in state of affairs during the financial year. Corporate Governance Statement Refer to the governance page of Uscom Limited’s website. Operating and financial review The operating and financial review is stated per the Chairman’s letter on pages 2-7. Events after the reporting date No matters or circumstances have arisen since the end of the financial year to the date of this report, that has significantly affected or may significantly affect the activities of the Consolidated Entity, the results of those activities or the state of affairs of the Consolidated Entity in the ensuing or any subsequent financial year. Future developments Other than the business activities described in the annual report and, in particular, those matters discussed in the Operating and Financial Review, the Board is not aware of any likely developments in the foreseeable future which may materially impact on the financial outlook of the Consolidated Entity. Environmental regulations The Consolidated Entity’s operations are not subject to significant environmental regulation under the law of the Commonwealth and State. Indemnifying officers The Consolidated Entity has paid premiums to insure all Directors and Executives against liabilities for costs and expenses incurred by them in defending any legal proceedings arising out of their conduct while acting in the capacity of Director of the Company, other than conduct involving a wilful breach of duty in relation to the Company. Proceedings on behalf of the Consolidated Entity No person has applied to the Court under section 237 of the Corporations Act 2001 for leave to bring proceedings on behalf of the Consolidated Entity, or to intervene in any proceedings to which the Consolidated Entity is a party, for the purpose of taking responsibility on behalf of the Consolidated Entity for all or part of those proceedings. No proceedings have been brought or intervened in on behalf of the Consolidated Entity with leave of the Court under section 237 of the Corporations Act 2001. Non-audit services The Consolidated Entity may decide to employ the auditor on assignments additional to their audit duties where the auditor’s expertise and experience with the Consolidated Entity are important. The Directors are of the opinion that the provision of non-audit services as disclosed in note 25 in the financial report does not compromise the external auditor’s independence as outlined in the Corporations Act 2001 for the following reasons: ANNUAL REPORT 2018 | Uscom Limited | Page 10 DIRECTOR’S REPORT • All non-audit services have been reviewed and approved to ensure that they do not impact the integrity and objectivity of the auditor, and • None of the services undermine the general principles relating to auditor independence as set out in the Code of • Conduct APES110 Code of Ethics of Professional Accountants issued by the Accounting. Professional and Ethical Standards Board, including reviewing or auditing the auditor’s own work, acting in management decision making capacity for the Company, acting as advocate for the Company or jointly sharing economic risks and rewards. Refer to note 25 of the financial statements on page 40 for details of auditors’ remuneration. The auditor’s independence declaration as required under section 307C of the Corporation Act is set out on page 16 and forms part of the Directors’ Report. BDO East Coast Partnership continues in office in accordance with section 327 of the Corporations Act 2001. Remuneration report (Audited) This remuneration report has been prepared by the Directors of Uscom Ltd to comply with the Corporations Act 2001 and the key management personnel (KMP) disclosures required under Australian Accounting Standards AASB 124 – Related Party Disclosures. Key management personnel The following were key management personnel of the Entity at the start of the financial year to the date of this report unless otherwise stated: Non-Executive Directors Sheena Jack, Non-Executive Director Christian Bernecker, Non-Executive Director Chao Xiao He, Non-Executive Director (Resigned on 23 May 2018) Executive Directors Rob Phillips, Executive Director, Chairman, Chief Executive Officer Senior Executives Nick Schicht, General Manager In the Directors’ opinion, there are no other Executives of the Entity. Remuneration policies The Board is responsible for reviewing the remuneration policies and practices of the Consolidated Entity, including the compensation arrangements of Executive Directors, Non-Executive Directors and Senior Executives. The Consolidated Entity has adopted remuneration policies based on performance and contribution for determining the nature and amount of emoluments of Board Members and Senior Executives. The objective of these policies is to: • Make Uscom Ltd and its Controlled Entities an employer of choice • Attract and retain the highest calibre personnel • Encourage a culture of reward for effort and contribution • Set incentives that reward short and medium term performance for the Consolidated Entity • Encourage professional and personal development In the case of Senior Executives, a recommendation for compensation review will be made by the Chairman to the Board, which will conduct a performance review. Non-Executive Directors The Board determines the Non-Executive Director remuneration by independent market data for comparative Companies. As at the date of this report the maximum aggregate remuneration payable out of the funds of the Entity to Non-Executive Directors of the Consolidated Entity for their services as Directors including their service on a committee of Directors is $165,000 per annum. Non-Executive Directors do not receive any performance related remuneration, therefore they do not receive bonuses or non- cash benefits. ANNUAL REPORT 2018 | Uscom Limited | Page 11 DIRECTOR’S REPORT Non-Executive Directors’ retirement payments are limited to compulsory employer superannuation. Executive Directors and Senior Executives remuneration The Consolidated Entity’s remuneration policy directs that the remuneration package appropriately reflects the Executives’ duties and responsibilities and that remuneration levels attract and retain high calibre Executives with the skills necessary to successfully manage the Consolidated Entity’s operations and achieve its strategic and financial objectives. The total remuneration packages of Executive Directors and Senior Executives are on a salary basis. In addition to base salary, the Company has a policy of rewarding extraordinary contribution to the growth of the Company with the grant of an annual discretionary cash bonus and options under the Consolidated Entity’s Employee Share Option Plan. Executives are also entitled to be paid for their reasonable travel, accommodation and other expenses incurred in consequence on the execution of duties. Other than the Uscom Ltd Employee Share Option Plan, the Consolidated Entity does not provide any other non-cash benefits in lieu of base salary to Executives. Remuneration packages for Executive Directors and Senior Executives generally consist of three components: • Fixed remuneration which is made up of cash salary, salary sacrifice components and superannuation • Short term incentives • Long term incentives which include issuing options pursuant to the Uscom Ltd Employee Share Option Plan. Fixed remuneration Senior Executives who possess a high level of skill and experience are offered a competitive base salary. The performance of each Executive will be reviewed annually. Following the review, the Consolidated Entity may in its sole discretion increase the salary based on that Executive’s performance, productivity and such other matters as the Board considers relevant. Superannuation contribution by the Consolidated Entity is limited to the statutory level of wages and salaries. Short-term incentives The remuneration of Uscom Ltd Senior Executives does not include any short-term incentive bonuses as part of their employment conditions. The Board may however approve discretionary bonuses to Executives in relation to certain milestones being achieved. Long-term incentives The Consolidated Entity has adopted an Equity Incentive Plan for the benefit of the Executive Director, an employee, contractor, consultant or any other person whom the Board determines to be eligible to participate in the Plans. The Board, at its discretion, may approve the issue of options and rights under the Equity Incentive Plan to the Senior Executives. The vesting of options and rights issued may be conditional upon the achievement of performance hurdles determined by the Board from time to time. The Board may propose the issue of options and rights to Directors, however this will be subject to shareholder approval at the Annual General Meeting. Independent data from applicable sources may be requested by the Board to assess whether the performance hurdles have been met. Service agreements The Consolidated Entity has entered into an employment agreement with the Executives that • Outlines the components of remuneration payable; and • Specifies termination conditions. Details of the employment agreement are as follows: Each Executive may not, during the term of the employment agreement, perform work for any other person, corporation or business without the prior written consent of the Consolidated Entity. The employment terms do not prescribe the duration of employment for executives. Due to the small number of Executives the remuneration committee comprises the Board of Directors which is made up of two Non-Executive Directors. Reference is made to external market information in order to retain the most suitable Executives for meeting the entity’s goals. Executive Directors are excluded from discussions on their remuneration. The remuneration of key Executives are not linked with the Consolidated Entity’s performance as the focus is on retention of key Executives to ensure ANNUAL REPORT 2018 | Uscom Limited | Page 12 DIRECTOR’S REPORT growth and traction in what is a new market. The Board of Directors will consider linking executive remuneration to the Consolidated Entity’s performance once the Consolidated Entity has sufficient market traction. Termination Despite anything to the contrary in the agreement, the Consolidated Entity or the Executive may terminate the employment at any time by giving the other party 3 months’ notice in writing. If either the Consolidated Entity or the Executive gives notice of termination, the Consolidated Entity may, at its discretion, choose to terminate the Executive’s employment immediately or at any time during the notice period and pay the Executive an amount equal to the salary due to them for the residual period of notice at the time of termination. Where the Executive gives less than 3 months’ written notice, the Consolidated Entity may withhold from the Executive’s final payment an amount equal to the shortfall in the notice period. The employment of each Executive may be terminated immediately without notice or payment in lieu in the event of any serious or persistent breach of the agreement, any serious misconduct or wilful neglect of duties, in the event of bankruptcy or any arrangement or compensation being made with creditors, on conviction of a criminal offence, permanent incapacity of the Executive or a consistent failure to carry out duties in a manner satisfactory to the Consolidated Entity. Key management personnel remuneration Remuneration includes salaries, benefits and superannuation contributions in respect of the financial year 2018. Remuneration includes salaries, benefits and superannuation contributions in respect of the financial year 2017. Short term benefits Post-employment benefits Directors’ Base Fee $ 35,000 38,325 - Base salary Superannuation $ - - - $ 3,325 - - Equity Share-based payment $ - - 19,163 Total remuneration Performance related - 229,000 21,755 85,862 336,617 - 73,325 200,000 429,000 19,000 44,080 29,811 134,836 248,811 681,241 Short term benefits Post-employment benefits Directors’ Base Fee $ 35,000 38,325 - Base salary Superannuation $ - - - $ 3,325 - - Equity Share-based payment $ - - 38,325 Total remuneration Performance related - 229,000 33,253 589,194 851,447 - 73,325 189,000 418,000 17,955 54,533 19,211 646,730 226,166 1,192,588 $ 38,325 38,325 19,163 $ 38,325 38,325 38,325 % - - - 26% 12% 20% % - - - 69% 8% 51% Non-Executive Director S Jack C Bernecker C X He Executive Director R Phillips Senior Executive N Schicht Total Non-Executive Director S Jack C Bernecker C X He Executive Director R Phillips Senior Executive N Schicht Total Equity Incentive Plan The Consolidated Entity has adopted an Equity Incentive Plan for the benefit of an employee, contractor, consultant or executive director of the Group or any other person whom the Board determines to be eligible to participate in the Plans. The purpose of the Plan is to: • provide Eligible Persons with an incentive plan which recognises ongoing contribution to the achievement by the Company of its strategic goals thereby encouraging the mutual interdependence of Participants and the Company; ANNUAL REPORT 2018 | Uscom Limited | Page 13 DIRECTOR’S REPORT • • • align the interests of Participants with shareholders of the Company through the sharing of a personal interest in the future growth and development of the Company as represented in the price of the Company’s ordinary fully paid shares; encourage Eligible Persons to improve the performance of the Company and its total return to Shareholders; and provide a means of attracting and retaining skilled and experienced employees. Under the Plan, the Consolidated Entity will be able to grant short-term incentive and long-term incentive awards to Eligible Employees (including Executive Directors). The Plan will provide the Board with the flexibility to grant equity incentives to Eligible Persons in the form of Plan Shares, rights or Options, will only vest on the satisfaction of appropriate hurdles. Number of rights over ordinary shares held by Directors and Senior Executives Balance Granted Exercised 1 July 2017 No. During FY2018 No. During FY2018 No. Lapsed / Cancelled During FY2018 No. Balance Total vested Total unexercisable 30 June 2018 30 June 2018 30 June 2018 No. No. No. Non-Executive Director S Jack C Bernecker C X He Executive Director R Phillips Senior Executive N Schicht Total - - 2,136,364 450,000 2,586,364 - - - - - - - (2,136,364) - (2,136,364) - - - - - - - - 450,000 450,000 - - - - - - - - 450,000 450,000 Further details of the options are disclosed in note 18 of the financial statements. Details of rights outstanding as at end of year Holders No. Grant date 1 (Executive) Total 26 November 2014 Exercisable at 30 June 2018 % 0% Expiry date 1 July 2020 30 June 2018 Outstanding Right No. 450,000 450,000 Exercise Price $ 0.00 Issued date fair value $ 0.19 450,000 Performance Rights were issued to Nick Schicht on 26 November 2014, vesting is dependent on performance hurdles on 1 July 2018, 1 July 2019 and 1 July 2020. Consideration payable upon vesting is $nil. Number ordinary shares held by Directors and Senior Executives Balance Received as Options/Rights 1 July 2017 Remuneration Exercised No. No. No. Purchased on market Non-Executive Director S Jack C Bernecker C X He Executive Director R Phillips Senior Executive N Schicht Total 800,000 - - 21,352,794 218,200 22,370,994 - - - - 100,000 100,000 - - - 2,136,364 - 2,136,364 Balance 30 June 2018 No. 800,000(1) - - 7,000 23,496,158(2) 7,000 318,200(3) 24,614,358 *Net change other refers to share purchased or sold during the financial year, or cessation of categorisation as a Director or Senior Executive. (1) All these ordinary shares are held by a family associate. (2) 13,493,525 of these ordinary shares are held by Australian Cardiac Sonography Pty Ltd as trustee for the Phillips Superannuation fund. (3) 10,000 of these ordinary shares are held by a family associate. ANNUAL REPORT 2018 | Uscom Limited | Page 14 DIRECTOR’S REPORT Additional Information The earnings of the consolidated entity for the five years to 30 June 2018 are summarised below: 2018 2017 2016 2015 2014 $ $ $ $ $ Sales Revenue 2,168,051 2,723,359 2,482,925 1,515,381 1,056,502 Loss after income tax (1,960,923) (1,800,849) (1,915,029) (1,215,654) (1,520,500) The factors that are considered to affect total shareholders return (‘TSR’) are summarised below: 2018 2017 2016 2015 2014 Share Price at financial year end ($) Total dividends declared (cents per share) Basic earnings declared (cents per share) 0.17 - (1.6) 0.19 - (1.6) 0.25 - (2.0) 0.19 - (1.5) 0.22 - (2.0) This concludes the remuneration report, which has been audited. This Directors’ report is signed in accordance with a resolution of the Board of Directors, pursuant to section 298(2)(a) of the Corporations Act 2001. Associate Professor Rob Phillips Executive Director - Chairman Sydney, 21 August 2018 ANNUAL REPORT 2018 | Uscom Limited | Page 15 AUDITOR’S INDEPENDENCE DECLARATION 16 Tel: +61 2 9251 4100 Fax: +61 2 9240 9821 www.bdo.com.au Level 11, 1 Margaret St Sydney NSW 2000 Australia DECLARATION OF INDEPENDENCE BY GARETH FEW TO THE DIRECTORS OF USCOM LIMITED As lead auditor of Uscom Limited for the year ended 30 June 2018, I declare that, to the best of my knowledge and belief, there have been: 1. No contraventions of the auditor independence requirements of the Corporations Act 2001 in relation to the audit; and 2. No contraventions of any applicable code of professional conduct in relation to the audit. This declaration is in respect of Uscom Limited and the entities it controlled during the year. Gareth Few Partner BDO East Coast Partnership Sydney, 21 August 2018 BDO East Coast Partnership ABN 83 236 985 726 is a member of a national association of independent entities which are all members of BDO (Australia) Ltd ABN 77 050 110 275, an Australian company limited by guarantee. BDO East Coast Partnership and BDO (Australia) Ltd are members of BDO International Ltd, a UK company limited by guarantee, and form part of the international BDO network of independent member firms. Liability limited by a scheme approved under Professional Standards Legislation, other than for the acts or omissions of financial services licensees. ANNUAL REPORT 2018 | Uscom Limited | Page 16 STATEMENT OF PROFIT OR LOSS & OTHER COMPREHENSIVE INCOME FOR YEAR ENDED 30 JUNE 2018 STATEMENT OF PROFIT OR LOSS & OTHER COMPREHENSIVE INCOME Continuing operations Revenue and other income Raw materials and consumables used Expenses from continuing activities Loss before income tax from continuing operations Income tax Loss after income tax from continuing operations Other comprehensive income Items that may be reclassified subsequently to profit or loss Foreign currency translation difference for foreign operations, net of tax Other comprehensive income for the year, net of tax Note 3 4 5 6 Consolidated 2018 $ 2017 $ 2,861,708 3,498,959 (605,348) (711,203) (4,212,655) (4,587,152) (1,956,295) (1,799,396) (4,628) (1,453) (1,960,923) (1,800,849) 154 154 9,083 9,083 Total comprehensive loss for the year (1,960,769) (1,791,766) Attributable to: Owners of the Company (1,960,769) (1,791,766) Total comprehensive loss for the year (1,960,769) (1,791,766) Earnings per share from continuing operations attributable to the owners of the Company Earnings per share (EPS) Basic earnings per share (cents per share) Diluted earnings per share (cents per share) 7 7 (1.6) (1.6) (1.6) (1.6) This Statement of Profit or Loss and Other Comprehensive Income is to be read in conjunction with the attached notes. ANNUAL REPORT 2018 | Uscom Limited | Page 17 STATEMENT OF FINANCIAL DECISION AS AT 30 JUNE 2018 STATEMENT OF FINANCIAL DECISION Current assets Cash and cash equivalents Trade and other receivables Inventories Term deposit Tax asset Other assets Total current assets Non-current assets Bank guarantee Plant and equipment Intangible assets Total non-current assets Total assets Current liabilities Trade and other payables Current provisions Total current liabilities Non-current liabilities Non-current provisions Total non-current liabilities Total liabilities Net assets Equity Issued capital Options and rights reserve Accumulated losses Foreign currency translation reserve Consolidated 2018 $ 2017 $ Note 8 9 10 11 12 13 14 15 16 16 2,493,575 249,289 494,809 - 498,060 163,138 3,898,871 83,457 238,456 1,154,732 1,476,645 1,663,565 196,063 492,209 41,569 503,212 134,706 3,031,324 - 118,671 1,336,248 1,454,919 5,375,516 4,486,243 275,023 215,687 490,710 446,349 236,330 682,679 40,048 40,048 25,552 25,552 530,758 708,231 4,844,758 3,778,012 17 18 6 19 33,254,701 2,813,371 (31,295,392) 72,078 30,332,259 2,708,298 (29,334,469) 71,924 Total equity 4,844,758 3,778,012 This Statement of Financial Position is to be read in conjunction with the attached notes. ANNUAL REPORT 2018 | Uscom Limited | Page 18 STATEMENT OF CHANGES IN EQUITY FOR YEAR ENDED 30 JUNE 2018 STATEMENT OF CHANGES IN EQUITY Issued Capital Options and rights Reserve Accumulated Losses Foreign Currency Translation Reserve Total Consolidated $ $ $ $ $ Balance at 30 June 2016 30,308,877 2,099,893 (27,533,620) 62,841 4,937,991 Loss for the year Other comprehensive income Total comprehensive income for the year Transactions with owners in their capacity as owners: Shares issued Transaction costs on shares issued Share-based payments - - - 29,750 (6,368) - - - - - - 608,405 (1,800,849) - (1,800,849) - 9,083 9,083 (1,800,849) 9,083 (1,791,766) - - - - - - 29,750 (6,368) 608,405 Balance at 30 June 2017 30,332,259 2,708,298 (29,334,469) 71,924 3,778,012 Loss for the year Other comprehensive income Total Comprehensive Income for the year Transactions with Owners in their capacity as owners: Shares issued Transaction costs on shares issued Share-based payments - - - 3,088,625 (166,183) - - - - - - 105,073 (1,960,923) - (1,960,923) - (1,960,923) 154 154 154 (1,960,769) - - - - - - 3,088,625 (166,183) 105,073 Balance at 30 June 2018 33,254,701 2,813,371 (31,295,392) 72,078 4,844,758 This Statement of Changes in Equity is to be read in conjunction with the attached notes. ANNUAL REPORT 2018 | Uscom Limited | Page 19 STATEMENT OF CASH FLOWS NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 30 JUNE 2018 STATEMENT OF CASH FLOWS Cash flows from operating activities Receipts from customers (inclusive of GST) Interest received Interest expense Payments to suppliers and employees (inclusive of GST) Grant and other income received Consolidated 2018 $ 2017 $ Note 2,118,093 2,808,137 8,743 (3,406) 15,338 - (4,449,907) (4,472,829) 629,852 697,312 Net cash used in operating activities 20(b) (1,696,625) (952,042) Cash flows from investing activities Purchase of patents and trademarks Purchase of plant and equipment Term deposit Acquisition of Thor Laboratories Net cash used in investing activities Cash flows from financing activities Issue of shares (net of share issue cost) (65,025) (171,838) (41,888) (60,000) (48,427) (57,552) (41,569) (100,000) (338,751) (247,548) 17 2,864,616 23,382 Net cash provided by financing activities 2,864,616 23,382 Net increase/(decrease) in cash held Cash and cash equivalents at the beginning of the year Exchange rate adjustment for opening balance 829,240 (1,176,208) 1,663,565 2,839,773 770 - Cash and cash equivalents at the end of the year 20 (a) 2,493,575 1,663,565 This Statement of Cash Flows is to be read in conjunction with the attached notes. ANNUAL REPORT 2018 | Uscom Limited | Page 20 NOTES TO FINANCIAL STATEMENTS NOTES TO FINANCIAL STATEMENTS Note 1: New accounting standards and interpretations In the current year, the Group has adopted all of the new and revised Standards and Interpretations issued by the Australian Accounting Standards Board (the AASB) that are relevant to its operations and effective for the current annual reporting period. The adoption of these new and revised Standards and Interpretations did not have any material financial impact on the amounts recognised and the disclosures presented in the financial statements of the Group. A number of new standards and amendments to standards are effective for annual periods beginning after 1 July 2018. Whilst earlier application is permitted, the Group has not early adopted the following new or amended standards in preparing these consolidated financial statements. A discussion of those future requirements and their impact on the Group is as follows: AASB 9: Financial Instruments Mandatory and anticipated date of application: 1st July 2018 The Standard replaces AASB 139 Financial Instruments: Recognition and Measurement. AASB 9 includes revised guidance on the classification and measurement of financial instruments, including a new expected credit loss model for calculation of impairment on financial assets and new general hedge accounting requirements. It also carried forward guidance on recognition and derecognition of financial instruments from AASB139. Assessment of Impact The Group has assessed the new standard and based on its financial assets and liabilities, the key impact of the standard on the Group will be in relation to trade debtors and the assessment of the provision for doubtful debts under the expected credit loss model. The expected credit loss model requires an entity to account for expected credit losses and changes in those expected credit losses at each reporting date to reflect changes. The Group has assessed the impact of applying the expected credit loss model and has concluded that the provision for impairment of trade receivables will increase upon the adoption of AASB 9 on 1 July 2018 due to the earlier recognition of credit losses. Additional disclosures regarding expected credit losses will also be required. AASB 15: Revenue from Contracts with Customers Mandatory and anticipated date of application: 1st July 2018 AASB 15 establishes a single comprehensive five-step model for entities to use in accounting for revenue arising from contracts with customers. AASB 15 will supersede the current revenue recognition guidance including AASB 118 Revenue, AASB 111 Construction Contracts and the related interpretations when it becomes effective. Assessment of Impact The Group has assessed the impact of adopting AASB 15 on its key revenue streams and Based on the work performed to date the findings indicate that the application of AASB15 will not have a material impact on the recognition of revenue. AASB 16: Leases Mandatory and anticipated date of application: 1st July 2019 AASB 16 introduces a comprehensive model for the identification of lease arrangements and accounting treatments for both lessors and lessees. AASB16 will supersede the current lease guidance including AASB 117 Leases and the related interpretations when it becomes effective. AASB 16 distinguishes leases and service contracts on the basis of whether an identified asset is controlled by a customer. Distinctions of operating leases (off balance sheet) and finance leases (on balance sheet) are removed for lessee accounting, and are replaced by a mode where a right-of-use asset and a corresponding liability have to be recognised for all leases by lessees (i.e. all on balance sheet) except for short-term leases and leases of low value assets. Assessment of Impact As at 30 June 2018, the Group has non-cancellable operating lease commitments of $728,221 (Note 24). The Group is in the process of completing an assessment of the impact of adoption of AASB 16 on these commitments. The full financial impact of adopting AASB 16 has not yet been determined, however the following impacts are expected on implementation date: ANNUAL REPORT 2018 | Uscom Limited | Page 21 NOTES TO FINANCIAL STATEMENTS Note 1: New accounting standards and interpretations (continued) Finance costs will increase due to the impact of the interest component of the lease liability. • A material right-of-use asset and a lease liability will be recognised on the Balance Sheet. • • Depreciation expense will increase due to depreciation of the right-of-use asset over the lease term. • • Lease rental operating expenses will reduce to nil. In the Cash Flow Statement, operating cash outflows will decrease and financing cash outflows will increase as repayment of the principal balance in the lease liability will be classified as a financing activity. Note 2: Statement of significant accounting policies (a) The financial report covers the Consolidated Entity of Uscom Ltd and its Controlled Entities. Uscom Ltd is a listed public company, incorporated and domiciled in Australia. Introduction Operations and principal activities Uscom Ltd is engaged in the development, design, manufacture and marketing of non-invasive cardiovascular and pulmonary monitoring devices. Uscom Ltd owns a portfolio of intellectual property relating to the technology and techniques associated with these devices and manages a worldwide network of distribution partners for the sale of its equipment to hospitals and other medical care locations. Scope of financial statements The financial report is a general purpose financial report that has been prepared in accordance with Australian Accounting Standards, Australian Accounting Interpretations, the Corporations Act 2001 and complies with other requirements of the law, as appropriate for-profit oriented entities. The financial report complies with Australian Accounting Standards as issued by the Australian Accounting Standards Board and International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board. Currency The financial report is presented in Australian dollars, which is the Parent Company’s functional and presentational currency. Historical Cost Convention This financial report has been prepared under the Historical Cost Convention. Reporting period The financial report is presented for the year ended 30 June 2018. The comparative reporting period was for the year ended 30 June 2017. Comparatives Where required by Accounting Standards comparative figures have been adjusted to conform with changes in presentation for the current financial year. Registered office Level 8, Suite 2, 66 Clarence Street, Sydney NSW 2000. Authorisation of financial report The financial report was authorised for issue on 21 August 2018 by the Directors. (b) Overall policy The principal accounting policies adopted by the Consolidated Entity are stated in order to assist in the general understanding of the financial report. Significant judgment and key assumptions (c) The Directors evaluate estimates and judgements incorporated into the financial report based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both externally and within the Entity. The Consolidated Entity assesses impairment at each reporting date by evaluating conditions specific to the group that may lead to impairment of assets. Where an impairment trigger exists, the recoverable amount of the asset is determined. The Consolidated Entity assesses impairment of non-financial assets other than goodwill and other indefinite life intangible assets at each reporting date by evaluating conditions specific to the consolidated entity and to the particular asset that may ANNUAL REPORT 2018 | Uscom Limited | Page 22 NOTES TO FINANCIAL STATEMENTS Note 2: Statement of significant accounting policies (continued) lead to impairment. If an impairment trigger exists, the recoverable amount of the asset is determined. This involves fair value less costs of disposal or value-in-use calculations, which incorporate a number of key estimates and assumptions. (d) Financial assets and financial liabilities Financial assets and financial liabilities are recognised on the Statement of Financial Position when the Consolidated Entity becomes party to the contractual provisions of the financial instrument. A financial asset is derecognised when the contractual rights to the cash flows from the financial assets expire or are transferred and no longer controlled by the Entity. A financial liability is removed from the statement of financial position when the obligation specified in the contract is discharged or cancelled or expires. Upon initial recognition a financial asset or financial liability is designated as at fair value through profit or loss except for investments in equity instruments that do not have a quoted market price in an active market and whose fair value cannot be reliably measured. A gain or loss arising from a change in the fair value of a financial asset or financial liability classified as at fair value through profit or loss is recognised in the statement of profit and loss and other comprehensive income. Financial assets not measured at fair value comprise receivables and investment in subsidiary. These are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market and are measured at amortised cost using the effective interest method. Available-for-sale financial assets include other financial assets, comprising investments in subsidiaries, not included in the above categories. Available-for-sale financial assets are reflected at fair value. Unrealised gains and losses arising from changes in fair value are taken directly to equity. Financial liabilities comprise of trade and other payables, and borrowings and are measured at amortised cost using the effective interest method. Trade accounts payable represent the principal amounts outstanding at reporting date plus, where applicable, any accrued interest. The amortised cost of a financial asset or a financial liability is the amount initially recognised minus principal repayments, plus or minus cumulative amortisation of any difference between the initial amount and maturity amount and minus any write-down for impairment or uncollectibility. Financial assets, other than those at fair value through profit or loss, are reassessed for indicators of impairment at each reporting date. Financial assets are impaired where there is objective evidence that as a result of one or more events that occurred after the initial recognition of the financial asset the estimated future cash flows of the investment have been impacted. For financial assets carried at amortised cost, the amount of the impairment is the difference between the asset’s carrying amount and the present value of estimated future cash flows, discounted at the original effective interest rate. The carrying amount of the financial asset is reduced by the impairment loss directly for all financial assets with the exception of trade receivables where the carrying amount is reduced through the use of an allowance account. When a trade receivable is uncollectible, it is written off against the allowance account. Subsequent recoveries of amounts previously written off are credited against the allowance account. Changes in the carrying amount of the allowance account are recognised in profit or loss. With the exception of available-for-sale equity instruments, if, in a subsequent period, the amount of the impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognised, the previously recognised impairment loss is revered through profit or loss to the extent the carrying amount of the investment at the date the impairment is reversed does not exceed what the amortised cost would have been had the impairment not been recognised. (e) Principles of consolidation A Controlled Entity is any entity Uscom Ltd has the power to control the financial and operating policies of so as to obtain benefits from its activities. ANNUAL REPORT 2018 | Uscom Limited | Page 23 NOTES TO FINANCIAL STATEMENTS Note 2: Statement of significant accounting policies (continued) A list of Controlled Entities is contained in note 22 to the financial statements. All Controlled Entities have a June financial year- end. All inter-company balances and transactions between Entities in the Consolidated Group, including any unrealised profits or losses, have been eliminated on consolidation. Accounting policies of Subsidiaries have been changed where necessary to ensure consistencies with those polices applied by the Parent Entity. On consolidation, the assets and liabilities of the Consolidated Entity’s overseas operations are translated at exchange rates prevailing at the reporting dates. Income and expense items are translated at the average exchange rates for the period unless exchange rates fluctuate significantly. Exchange differences arising, if any, are recognised in the foreign currency translation reserve, and are recognised in statement of profit or loss and other comprehensive income on disposal of the foreign operation. Foreign currency transactions and balances (f) All foreign currency transactions during the financial year are brought to account using the exchange rate in effect at the date of the transaction. Foreign currency monetary items at reporting date are translated at the exchange rate existing at reporting date. Non-monetary assets and liabilities carried at fair value that are denominated in foreign currencies are translated at the rates prevailing at the date when the fair value was determined. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated. The gains and losses from conversion of assets and liabilities, whether realised or unrealised, are included in profit or loss from continuous operations as they arise. Investments (g) Investments in Controlled Entities are carried at the lower of cost and recoverable amount. (h) Share-based payment arrangement Uscom Ltd has adopted an Employee Share Option Plan for the benefit of Executive Directors and full-time or part-time staff members employed by the Consolidated Entity. Refer note 18 to the financial statements for details. Goods or services received or acquired in a share-based payment transaction are recognised as an increase in equity if the goods or services were received in an equity-settled share based payment transaction or as a liability if the goods and services were acquired in a cash settled share based payment transaction. For equity-settled share based transactions, goods or services received are measured directly at the fair value of the goods or services received provided this can be estimated reliably. If a reliable estimate cannot be made the value of the goods or services is determined indirectly by reference to the fair value of the equity instrument granted. Transactions with employees and others providing similar services are measured by reference to the fair value at grant date of the equity instrument granted. (i) Goods and services tax (GST) Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Tax Office. In these circumstances the GST is recognised as part of the cost of acquisition of the asset or as part of an item of the expense. Receivables and payables in the Statement of Financial Position are shown inclusive of GST. (j) Contingent liabilities A contingent loss is recognised as an expense and a liability if it is probable that future events will confirm that, after taking into account any related probable recovery, an asset has been impaired or a liability incurred and, a reasonable estimate of the amount of the resulting loss can be made. (k) Events after the reporting date Assets and liabilities are adjusted for events incurring after the reporting date that provide evidence of conditions existing at the reporting date. Important after reporting date events which do not meet these criteria are disclosed in note 28 to the financial statements. ANNUAL REPORT 2018 | Uscom Limited | Page 24 NOTES TO FINANCIAL STATEMENTS Note 3: Revenue and other income Operating revenue Sale of goods Other revenue Interest received Other income Grants – R&D tax incentive Grants – EU research grant Grants – EMDG Grants – Business growth grant Foreign exchange gain Sundry income Total other income Consolidated 2018 $ 2017 $ 2,168,051 2,723,359 31,100 15,338 489,126 148,969 - 3,850 15,500 5,112 662,557 558,550 110,195 76,925 - - 14,592 760,262 Total revenues and other income from continuing operations 2,861,708 3,498,959 Recognition and Measurement Revenue is measured at the fair value of the consideration received or receivable. Amounts are disclosed as revenue net of returns, discounts, allowances and goods and services tax (GST). The consolidated entity recognises revenue when the amount of revenue can be reliably measured, it is probable that the future economic benefits will flow to the entity and specific criteria have been met for each of the entity’s activities as described below. • Sale of goods Revenue from the sale of goods is recognised when all significant risks and rewards of ownership have been transferred to the buyer and when the other contractual obligations of the Entity are performed. • Revenue from rendering of services • Rendering of services consists of training, repair and product maintenance supplied to customers. Revenue is recognised when contractual obligations are expired and services are provided. Interest revenue Interest revenue is recognised on a proportional basis taking into account the interest rates applicable to the financial assets. • Government grants Government grants revenue is recognised at fair value when there is reasonable assurance that the grant will be received and the grant conditions will be met. Note 4: Expenses from continuing activities Depreciation and amortisation expenses Employee benefits expense Research and development expenses Advertising and marketing expenses Occupancy expenses Auditors remuneration (audit and review) Regulatory expenses Administrative expenses Exchange losses Finance costs Total expenses from continuing activities, excluding finance costs 304,303 1,711,313 845,436 519,658 197,445 65,522 105,066 459,002 - 4,910 4,212,655 284,650 2,264,511 614,117 575,094 185,610 61,541 88,524 453,096 50,918 9,091 4,587,152 Employee Benefits Expenses Employer contributions to defined contribution superannuation plans are recognised as an expense in the profit or loss as they are paid or payable. Refer to Note 16 for details on provisions for employee benefits. Share based expenses of $142,898 in 2018 (2017: $608,406) are included in employee benefits expenses above. ANNUAL REPORT 2018 | Uscom Limited | Page 25 NOTES TO FINANCIAL STATEMENTS Note 4: Expenses from continuing activities (continued) Research and development expenses Research & development costs are charged to the statement of profit or loss and other comprehensive income as incurred, or deferred where it is probable that sufficient future benefits will be derived so as to recover those deferred costs. Lease Operating lease payments, where the lessors effectively retain substantially all the risks and benefits of ownership of the lease items, are included in the determination of profit or loss in equal instalments over the period of the lease. Lease incentives received are recognised as an integral part of the total lease payments made and are spread on a basis representative of the pattern of benefits expected to be derived from the leased asset. Lease expenses of $197,445 in 2018 (2017: $171,387) are included in occupancy expenses above. Note 5: Income tax Major components of income tax Current income tax Income tax Reconciliation between income tax credit and prima facie tax on accounting loss Accounting loss before income tax Tax benefit at 27.5% in Australia, 15% in USA, 12% in Hungary (2017: 27.5% in Australia, 15% in USA, 12% in Hungary) Tax effect on non-taxable income and non-deductible expenses Temporary differences Deferred tax asset not brought to account Income tax Consolidated 2018 $ (4,628) (4,628) 2017 $ (1,453) (1,453) 1,956,295 1,799,396 462,679 (208,320) (12,589) (246,398) (4,628) 482,512 (322,407) (38,095) (123,463) (1,453) As at 30 June 2018, the Consolidated Entity had estimated unrecouped operating income tax losses of $20,012,191 (2017: $19,217,407). The benefit of these losses of $5,329,094 (2017: $5,100,599) has not been brought to account as it is not probable that the Consolidated Entity will have sufficient future gains available against which the deferred tax asset could be utilised. Note 6: Accumulated losses Accumulated losses at the beginning of the financial year Net loss attributable to members of the Entity Accumulated losses at the end of the financial year Note 7: Earnings per share Loss after tax used in calculation of basic and diluted EPS Weighted average number of ordinary shares during the year used in calculation of basic EPS Weighted average number of options outstanding Weighted average number of rights outstanding Weighted average number of ordinary shares outstanding during the year used in calculation of diluted EPS Basic earnings per share (cents per share) Diluted earnings per share (cents per share) (29,334,469) (1,960,923) (27,533,620) (1,800,849) (31,295,392) (29,334,469) (1,960,923) (1,800,849) Number Number 125,569,613 110,601,128 474,908 1,436,426 4,980,545 4,155,480 127,480,947 119,737,153 (1.6) (1.6) (1.6) (1.6) The options and rights in existence have an anti-dilutive effect on EPS, therefore there is no difference between basic earnings per share and diluted earnings per share as shown above. ANNUAL REPORT 2018 | Uscom Limited | Page 26 NOTES TO FINANCIAL STATEMENTS Note 8: Cash and cash equivalents Cash on hand Bank: Cheque accounts Bank: Cash management Bank: Term deposits Total cash and cash equivalents Consolidated 2018 $ 2017 $ 1,569 479,906 28,551 1,983,549 2,493,575 2,283 1,625,720 35,562 - 1,663,565 Cash and cash equivalents comprise cash on hand and at call deposits with banks or financial institutions. Note 9: Trade and other receivables Current Trade receivables Total current receivables 249,289 249,289 196,063 196,063 Trade receivables are non-interest bearing and on an average of 45 day terms. Details of trade receivables past due but not impaired are disclosed in note 21. Trade receivables and other receivables represent the principal amounts due at reporting date plus accrued interest and less, where applicable, any unearned income and provision for doubtful accounts. An estimated doubtful debt is made when collection of the full amount is no longer probable. Note 10: Inventories Current inventories at cost Raw materials Work in Progress Finished products Total inventories 262,016 128,406 104,387 494,809 305,686 105,927 80,596 492,209 Inventories are measured at the lower of cost or net realisable value. Costs are assigned on the basis of weighted average costs. Cost comprises all costs of purchase and conversion and an appropriate proportion of fixed and variable overheads, net of settlement discounts. Overheads are applied on the basis of normal operative capacity. The costs are recognised when materials are delivered to the Consolidated Entity. Note 11: Tax asset Income tax credit R & D tax incentive Total tax asset 8,934 489,126 498,060 11,480 491,732 503,212 Income tax Income taxes are accounted for using the Balance Sheet liability method whereby: • The tax consequences of recovering (settling) all assets (liabilities) are reflected in the financial statements; • Current and deferred tax is recognised as income or expenses except to the extent that the tax relates to equity items or to a business combination; • A deferred tax asset is recognised to the extent that it is probable that future taxable profit will be available to realise the asset; • Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realised or the liability settled. ANNUAL REPORT 2018 | Uscom Limited | Page 27 NOTES TO FINANCIAL STATEMENTS Note 11: Tax asset (continued) The charge for current income tax expense/credit is based on the profit or loss for the year adjusted for any non- assessable or disallowed items. It is credited using tax rates that have been enacted or are substantively enacted by the reporting date. Deferred tax is accounted for using the Balance Sheet liability method in respect of temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. Deferred tax is calculated at the tax rates that are expected to apply to the period when the asset is realised or liability is settled. Deferred tax is credited in the income statement except where it relates to items that may be credited directly to equity, in which case the deferred tax is adjusted directly against equity. Deferred income tax assets are recognised to the extent that it is probable that future tax profits will be available against which deductible temporary differences can be utilised. The amount of benefits brought to account or which may be realised in the future is based on the assumption that no adverse change will occur in income taxation legislation and the anticipation that the Consolidated Entity will derive sufficient future assessable income to enable the benefit to be realised and comply with the conditions of deductibility imposed by the law. R & D tax incentive Where the Consolidated Entity is entitled to a research and development tax offset, this is treated as other income in the period to which the entitlement relates. Note 12: Other assets Current Accrued income GST/VAT receivable Prepayments Total other current assets Note 13: Plant and equipment Plant and equipment at cost Accumulated depreciation – including foreign exchange impact Office furniture and equipment at cost Accumulated depreciation – including foreign exchange impact Computer software at cost Accumulated depreciation – including foreign exchange impact Low value asset pool at cost Accumulated depreciation – including foreign exchange impact Consolidated 2018 $ 2017 $ 22,356 63,090 77,692 163,138 1,623 72,018 61,065 134,706 701,628 (609,149) 92,479 174,005 (32,002) 142,003 33,535 (30,059) 3,476 50,314 (49,816) 498 709,437 (611,886) 97,551 71,052 (62,164) 8,888 45,727 (34,473) 11,254 51,508 (50,530) 978 Total plant and equipment 238,456 118,671 ANNUAL REPORT 2018 | Uscom Limited | Page 28 NOTES TO FINANCIAL STATEMENTS Note 13: Plant and equipment (continued) Movements in carrying amounts Plant and equipment Office furniture and equipment Computer software Low value asset pool Useful life Consolidated Entity Carrying amount at 1 July 2017 Additions Disposals Depreciation expense Carrying amount at 30 June 2018 2-7 years $ 97,551 29,825 - (34,897) 92,479 2-7 years $ 8,888 162,200 (15,384) (13,701) 142,003 3 years $ 11,254 - - (7,778) 3,476 3 years $ 978 906 - (1,386) 498 Property, plant and equipment are included at cost. Assets in plant and equipment are depreciated on diminishing value basis over their estimated useful lives covering a period of two to seven years. On disposal of an item of property, plant and equipment, the difference between the sales proceeds and the carrying amount of the asset is recognised as a gain or loss in the statement of profit or loss and other comprehensive income. The depreciation rates used for each class of depreciable assets are: Class Of Fixed Asset -Plant & Equipment - Office Furniture & Equipment - Computer Software - Low Value Pool Depreciation Rate 10% - 40% 15% 40% 37.5% Note 14: Intangible assets Non-current Patents at cost Accumulated amortisation and impairment Carrying amount at 30 June Regulatory approvals -acquisitions through business combinations Accumulated amortisation Carrying amount at 30 June Total intangible assets Movements in carrying amounts Patents carrying amount at 1 July Additions Impairment Amortisation Patents carrying amount at 30 June Regulatory approvals -acquisitions through business combinations Additions Impairment Amortisation Regulatory approvals carrying amount at 30 June Consolidated 2018 $ 2017 $ 1,910,711 (1,029,295) 881,416 630,730 (357,414) 273,316 1,154,732 936,786 65,025 - (120,395) 881,416 399,462 - - (126,146) 273,316 1,845,687 (908,901) 936,786 630,730 (231,268) 399,462 1,336,248 1,018,457 48,427 - (130,098) 936,786 525,608 - - (126,146) 399,462 Recognition and Measurement Intangibles are carried at cost less accumulated amortisation and impairment losses where applicable. Intangible assets acquired separately are capitalised at cost or if arising from a business combination at fair value as at the date of acquisition. ANNUAL REPORT 2018 | Uscom Limited | Page 29 NOTES TO FINANCIAL STATEMENTS Note 14: Intangible assets (continued) Intangible Assets comprise Intellectual Property in the form of Patents and Regulatory approvals (FDA and CE). Patents and Regulatory approvals have finite useful lives. The current amortisation charge in respect of Patents and Regulatory approvals is included under Expenses from Continuing Activities in the Statement of Profit or Loss and Other Comprehensive Income. Patents and Trademarks are valued in the financial statements at cost of acquisition less accumulated amortisation and are amortised on diminishing value basis at 12.5% per annum. The value of Regulatory Approvals was recognised at the acquisition of Thor Laboratories. Regulatory Approvals are amortised over 5 years on straight line basis from the date of acquisition. Impairment of assets At each reporting date, the Consolidated Entity reviews the carrying values of its tangible and intangible assets to determine whether there is any indication that those assets have been impaired. If such an indication exists, the recoverable amount of the asset, being the higher of the asset’s fair value less costs to sell and value in use, is compared to the asset’s carrying value. Any excess of the asset’s carrying value over its recoverable amount is expensed to the statement of profit or loss and other comprehensive income. In assessing value in use, the estimated future cash flows discounted to their present value using a pre- tax discount rate. Note 15: Trade and other payables Current Trade payables Sundry payables and accrued expenses Employee related payables Total payables Consolidated 2018 $ 2017 $ 132,542 95,330 47,151 275,023 111,985 232,365 101,999 446,349 Trade and other payables represent the liability outstanding at the end of the reporting period for goods and services received by the Group during the reporting period which remains unpaid. The balance is recognised as a current liability with the amount being normally paid within 30 days of recognition of the liability. The carrying amounts of the Group’s trade and other payables are denominated in Australian Dollars. For an analysis of the financial risks associated with trade and other payable refer to Note 21. Note 16: Provisions Current Provision for annual leave Provision for long service leave Non-current Provision for long service leave Provision for warranties Provision for make good (a) Aggregate employee benefits (b) Movement in employee benefits Balance at beginning of the year Additional provision Amounts used Balance at end of the year (c) Movement in warranties Balance at beginning of the year Additional provision Amounts used Balance at end of the year ANNUAL REPORT 2018 | Uscom Limited | Page 30 172,779 42,908 215,687 11,864 14,150 14,034 40,048 227,551 246,082 153,969 (172,500) 227,551 15,800 90 (1,740) 14,150 162,130 74,200 236,330 9,752 15,800 - 25,552 246,082 214,256 142,919 (111,093) 246,082 13,600 5,000 (2,800) 15,800 NOTES TO FINANCIAL STATEMENTS Note 16: Provisions (continued) Short term employee benefits Short term employee benefits are employee benefits (other than termination benefits and equity compensation benefits) which fall due wholly within 12 months after the end of the period in which employee services are rendered. They comprise wages, salaries, social security obligations, short-term compensation absences, profit sharing and bonuses payables within 12 months and non-mandatory benefits such as medical care, housing, car and service goods. The provision for employee entitlements to wages, salaries and annual leave represents the amount that the Consolidated Entity has a present obligation to pay resulting from employee services provided up to reporting date. The provision has been calculated after taking into consideration estimated future increases in wages and salaries and past experience regarding staff departures and includes related on-costs. The undiscounted amount of short-term benefits expected to be paid is recognised as an expense. Long term employee benefits Long term employee benefits include long-service leave, long-term disability benefits, deferred compensation and profit sharing and bonuses payable 12 months or more after the end of the period in which employee services are rendered. Warranties Provision is made in respect of the Consolidated Entity’s estimated liability on all products and services under warranty at reporting date. The provision is measured at the present value of future cash flows estimated to be required to settle the warranty obligation. The future cash flows have been estimated by reference to the Consolidated Entity’s history of warranty claims. Lease Make Good A provision for lease make good is recognised in relation to the properties held under operating lease. The Group recognises the provision for property leases which contain specific clauses to restore the property to a specific condition. The provision at balance date represents management’s best estimate of the present value of the future make good costs required. Note 17: Issued capital Issued capital Fully paid ordinary shares Total contributed equity Movement in issued capital Shares on issue at the beginning of the year 500,000 ordinary shares issued at 5.95 cents on 18 August 2016 3,272,728 ordinary shares issued at nil cost on 23 December 2016 250,000 ordinary shares issued at nil cost on 5 July 2017 100,000 ordinary shares issued at 16.5 cents on 6 September 2017 165,000 ordinary shares issued at 16.5 cents on 6 September 2017 52,000 ordinary shares issued at 20 cents on 7 December 2017 153,300 ordinary shares issued at 25 cents on 7 December 2017 1,500,000 ordinary shares issued at nil cost on 7 December 2017 22,044,998 ordinary shares issued at 13.5 cents on 21 December 2017 636,364 ordinary shares issued at nil cost on 8 January 2018 121,212 ordinary shares issued at 16.5 cents on 8 June 2018 Share issue costs Issued Equity at the end of the year Fully paid ordinary shares Ordinary shares at the beginning of the year Ordinary shares issued by exercise of option on 18 August 2016 Ordinary shares issued by exercise of rights on 23 December 2016 Ordinary shares issued on 5 July 2017 as per Thor acquisition agreement Ordinary shares issued on 6 September 2017 to an employee Ordinary shares issued on 6 September 2017 to employees ANNUAL REPORT 2018 | Uscom Limited | Page 31 Consolidated 2018 $ 2017 $ 33,254,701 30,332,259 33,254,701 30,332,259 30,332,259 - - - 16,500 27,225 10,500 38,325 - 2,976,075 - 20,000 (166,183) 30,308,877 29,750 - - - - - - - - - - (6,368) 33,254,701 30,332,259 Number 112,235,998 - - 250,000 100,000 165,000 Number 108,463,270 500,000 3,272,728 - - - NOTES TO FINANCIAL STATEMENTS Note 17: Issued capital (Continued) Ordinary shares issued on 7 December 2017 in lieu of FY2016 directors fees Ordinary shares issued on 7 December 2017 in lieu of FY2017 directors fees Ordinary shares issued by exercise of rights on 7 December 2017 Ordinary shares issued by private placement on 21 December 2017 Ordinary shares issued by exercise of rights on 8 January 2018 Ordinary shares issued at 16.5 cents on 8 June 2018 in lieu of salary Consolidated 2018 $ 2017 $ 52,500 153,300 1,500,000 22,044,998 636,364 121,212 - - - - - - Total ordinary shares at the end of the year 137,259,372 112,235,998 The Company’s authorised share capital amounted to 137,259,372 ordinary shares of no par value at 30 June 2018. Fully paid ordinary shares participate in dividends and the proceeds on winding up of the Company in proportion to the number of shares held. At shareholders meetings, each ordinary share is entitled to one vote when a poll is called, or via a show of hands. Note 18: Options and rights reserve The Consolidated Entity has adopted a new Equity Incentive Plan for the benefit of an employee, contractor, consultant, executive director of the Group or any other person whom the Board determines to be eligible to participate in the Plans. The Board may impose conditions, including performance related conditions, on the right to exercise any options and rights granted under the Equity Incentive Plan. The purpose of the Plan is to: • • • • provide Eligible Persons with an incentive plan which recognises ongoing contribution to the achievement by the Company of its strategic goals thereby encouraging the mutual interdependence of Participants and the Company; align the interests of Participants with shareholders of the Company through the sharing of a personal interest in the future growth and development of the Company as represented in the price of the Company’s ordinary fully paid shares; encourage Eligible Persons to improve the performance of the Company and its total return to Shareholders; and provide a means of attracting and retaining skilled and experienced employees. Under the Plan, the Consolidated Entity will be able to grant short-term incentive and long-term incentive awards to Eligible Employees (including Executive Directors). The Plan will provide the Board with the flexibility to grant equity incentives to Eligible Persons in the form of Plan Shares, rights or Options, will only vest on the satisfaction of appropriate hurdles. Effect of share-based payment transactions Share Option Plan Options and rights reserve balance at the beginning of the year Expenses arising from share-based payment transactions Options and rights reserve balance for Share Option Plan at the end of the year Consolidated 2018 $ 2017 $ 2,708,298 105,073 2,813,371 2,099,893 608,405 2,708,298 Movement in options during the financial year Movement during the financial year Opening number of options Lapsed during the financial year Exercised during the financial year Closing number of options Number of Options 2018 4,840,544 (4,765,544) - 75,000 Weighted average exercise price 0.23 0.25 - 0.17 Number of Options 2017 5,440,544 (100,000) (500,000) 4,840,544 Weighted average exercise price 0.21 0.06 0.06 0.23 ANNUAL REPORT 2018 | Uscom Limited | Page 32 NOTES TO FINANCIAL STATEMENTS Note 18: Options and rights reserve (continued) Details of options outstanding as at end of the year Holders No. Grant date Exercisable at 30 June 2018 Expiry date 1 (Consultant) 1 December 2014 100% 1 July 2018 Total % 30 June 2018 Outstanding Option No. 75,000 75,000 Exercise Price Issued date fair value $ 0.1700 $ 0.20 The options issued on 1 December 2014 were issued under the Equity Incentive plan. The options vest one third each on the issue day, 1 July 2015 and 1 July 2016 respectively. Fair value Fair value was measured using Blackscholes and the inputs to it were as follows: Weighted average share price Exercise price Option life Risk-free interest rate Expected dividends Expected volatility* $0.17 75,000 at $0.17 3 years 2.53% 0 % * Historical volatility has been the basis for determining the expected share price volatility as it is assumed that it is indicative of the future trade, which may not eventuate. Movement in rights during the financial year Rights at the beginning of the period Exercised during the period Rights at the end of the period Consolidated 2018 Number 2,586,364 (2,136,364) 450,000 2017 Number 5,859,092 (3,272,728) 2,586,364 450,000 Performance rights were issued to Nick Schicht on 26 November 2014 under the Equity Incentive Plan, vesting dependent on performance hurdles on 1 July 2018, 1 July 2019 and 1 July 2020. Consideration payable upon vesting is $nil. Note 19: Foreign currency translation reserve Opening balance Translation of financial statements of foreign Controlled Entities Closing balance $ 71,924 154 72,078 $ 62,841 9,083 71,924 Exchange differences arising on translation of the foreign controlled entity are taken to the foreign currency translation reserve. The reserve is recognised in profit or loss when the net investment is disposed of. ANNUAL REPORT 2018 | Uscom Limited | Page 33 NOTES TO FINANCIAL STATEMENTS Note 20: Cash flow information (a) Reconciliation of cash Cash at bank and on hand Total cash at end of year (b) Reconciliation of cash flow from operations to loss from continuing operations after income tax Loss from continuing operations after income tax Non cash flows in loss from continuing operations Depreciation Amortisation Options reserve Translation reserve (Increase)/decrease in assets Trade debtors Inventories Inventories transferred to PE Prepayments Tax credit Accrue income GST/VAT assets Increase/(decrease) in liabilities Trade payables Sundry payables and accrued expenses Employee related payables Employee provisions Other provisions Net cash used in operating activities Consolidated 2018 $ 2017 $ 2,493,575 2,493,575 1,663,565 1,663,565 (1,960,923) (1,800,849) 57,762 246,541 162,898 154 (53,226) (2,600) (10,936) (16,627) 5,152 (20,733) 8,928 20,557 (72,577) (54,848) (18,531) 12,384 (1,696,625) 28,406 256,244 608,406 9,083 71,688 (73,502) (15,318) (16,337) (73,696) (1,623) 20,293 39,174 (85,591) 47,554 31,826 2,200 (952,042) Note 21: Financial instruments Significant accounting policies (a) Details of the significant accounting policies and methods adopted, including the criteria of recognition, the basis of measurement and the basis on which income and expenses are recognised, in respect of each class of financial asset, financial liability and equity instrument are disclosed in note 2 to the financial statements. (b) Capital risk management The Consolidated Entity manages its capital to ensure that companies in the Consolidated Entity are able to continue as a going concern. The capital structure of the Entity consists of cash and cash equivalents (note 8 on page 27) and equity attributable to equity holders of the Parent Entity, comprising issued capital (note 17 on page 31), and accumulated losses (note 6 on page 26). (c) Outstanding contracts At 30 June 2018, there were no outstanding contracts. (d) Financial risk management objectives The Consolidated Entity’s principal financial instruments are cash and term deposit accounts. Its financial instruments risk is with interest rate risk on its cash and term deposits and liquidity risk for its term deposits. The Consolidated Entity does not enter into or trade financial instruments, including derivative financial instruments, for speculative purposes. The Board is updated monthly by management as to the amounts of funds available to the Consolidated Entity from either cash in the bank or term deposits, and continually monitors interest rate movements. ANNUAL REPORT 2018 | Uscom Limited | Page 34 NOTES TO FINANCIAL STATEMENTS Note 21: Financial instruments (continued) (e) Foreign currency risk management The Consolidated Entity undertakes certain transactions denominated in foreign currencies, hence exposures to exchange rate fluctuations arise. The Consolidated Entity does not have any forward foreign exchange contracts as at 30 June 2018 and is exposed to foreign currency risk on sales and purchases denominated in a currency other than Australian dollars. The currencies giving rise to this risk is primarily the US Dollar and Euro. The Consolidated Entity incurs costs in US Dollars for its operations which provide a natural hedge for a portion of income denominated in US Dollars. The carrying amount of the Consolidated Entity’s foreign currency denominated monetary assets and monetary liabilities at the reporting date is as follows: Cash Current trade debtors Current trade creditors Cash Current trade debtors Current trade creditors Cash Current trade debtors Current trade creditors Consolidated 2018 US$ 558,376 122,500 20,734 HUF 2,355,437 105,895 31,286,548 € 31,210 52,680 - 2017 US$ 1,065,122 104,830 19,411 HUF 10,502,924 982,905 16,317,946 € 98,408 39,530 3,755 Foreign currency sensitivity (f) The Consolidated Entity is mainly exposed to exchange rate risks arising from movements in the US Dollar, Euro and Hungarian forint (HUF) against the Australian Dollar, and the US Dollar from the translation of the operations of its Controlled Entity. The analysis below demonstrates the profit impact of a 10% movement of US Dollar and a 5% movement of Euro rates against the Australian Dollar with all other variables held constant. 10% and 5% are the sensitivity rates used when reporting foreign currency risk internally to key management personnel and represents management’s assessment of the possible change in foreign exchange rates. Profit/Loss - increase 10% (US$) and 5% (€) - decrease 10% (US$) and 5% (€) Consolidated 2018 $ (178,829) 178,829 2017 $ (226,898) 226,898 Interest rate risk management (g) The Consolidated Entity does not have any external loans or borrowings as at 30 June 2018 and is not exposed to interest rate risks related to debt. The Consolidated Entity is exposed to interest rate risk as companies in the Consolidated Entity hold cash and term deposits at both fixed and floating interest rates. The risk is managed by the Consolidated Entity maintaining an appropriate mix between both rates. Management continually monitors its cash requirements through forecasts and cash flow projections and moves funds between fixed and variable interest instruments to hold the maximum amount possible in instruments which pay the greater rate of interest. This limits the amount of risk associated with setting a policy on the mix of funds to be held in fixed or variable interest rate instruments. ANNUAL REPORT 2018 | Uscom Limited | Page 35 NOTES TO FINANCIAL STATEMENTS Note 21: Financial instruments (continued) (h) A 100 basis point increase or decrease is used when reporting interest rate risk internally to key management personnel and represents management’s assessment of the possible change in interest rates. Interest rate sensitivity Profit/Loss - increase 100 basis points - decrease 100 basis points Consolidated 2018 $ 3,110 (3,110) 2017 $ 1,534 (1,534) (i) Credit risk management Credit risk represents the loss that would be recognised if counterparties defaulted on its contractual obligations. The Consolidated Entity’s exposure and the credit ratings of its counterparties are continuously monitored and the aggregate value of transactions concluded is spread among approved counterparties. Credit exposure is controlled by counterparty limits that are reviewed and approved by the management annually. Ongoing credit evaluation is also performed on the financial condition of accounts receivable. The Consolidated Entity does not have significant credit risk exposure to any single counterparty or any group of counterparties having similar characteristics; because the current major counterparties are alliance distributors and public hospitals with approved funds available prior to purchases under most circumstances. The credit risk on financial assets of the Consolidated Entity, as recognised on the Statement of Financial Position, is the carrying amount, net of any allowance for doubtful debts. Credit risk in respect of cash and deposits is minimised as counterparties are recognised financial intermediaries with acceptable credit ratings determined by a recognised rating agency. Debtors outstanding but not impaired 0 - 45 days 46 – 90 days Over 90 days Total Consolidated 2018 $ 231,629 17,660 - 249,289 2017 $ 191,339 - - 191,339 No bad debt was written off during the year (2017: $Nil). There was no doubtful debt provision as at 30 June 2018 (2017: Nil). The outstanding debts $17,660 was received in July 2018 and the remaining $231,629 are not past due to the reporting date. Liquidity risk management (j) The objective for managing liquidity risk is to ensure the business has sufficient working capital or access to working capital as and when required. The Consolidated Entity limits its exposure to liquidity risk by holding the majority of its assets in cash or term deposits which can be quickly converted to cash if required. The carrying amounts of financial assets and financial liabilities recorded at cost approximate their fair values. The following table details the Consolidated Entity’s remaining contractual maturity for its non-derivative financial assets and liabilities. The table has been drawn up based on the undiscounted cash flows expected to be received/paid by the Consolidated Entity. ANNUAL REPORT 2018 | Uscom Limited | Page 36 2018 Financial assets Cash Term deposit Bank guarantee Trade receivables Other receivables Total financial assets Financial liabilities Trade creditors Payables Total financial liabilities Net financial assets Consolidated 2017 Financial assets Cash Term deposit Trade receivables Other receivables Total financial assets Financial liabilities Trade creditors Payables Total financial liabilities Net financial assets NOTES TO FINANCIAL STATEMENTS Note 21: Financial instruments (continued) Consolidated Weighted Average effective interest Rate % Floating interest $ Fixed interest rate maturing 1 to 5 years $ Within 1 year $ Non-interest bearing $ 0.0 2.5 2.85 - - - - - - - - - - - 1,983,549 - - - 1,983,549 - - - - - 83,457 - - 83,457 - - - 510,026 - - 249,289 85,446 844,761 132,542 47,151 179,693 1,983,549 83,457 665,068 2,732,074 Total $ 510,026 1,983,549 83,457 249,289 85,446 2,911,767 132,542 47,151 179,693 Weighted Average effective interest Rate % Floating interest $ Fixed interest rate maturing 1 to 5 years $ Within 1 year $ Non-interest bearing $ Total $ 0.0 2.5 45,474 - - - 45,474 - - - - 41,569 - - 41,569 - - - 45,474 41,569 - - - - - - - - - 1,618,091 - 196,063 73,641 1,663,565 41,569 196,063 73,641 1,887,795 1,974,838 111,985 101,999 213,984 111,985 101,999 213,984 1,673,811 1,760,854 2018 $ 2,732,074 498,060 494,809 77,692 238,456 1,154,732 (95,330) (255,735) 2017 $ 1,760,854 503,212 492,209 61,065 118,671 1,336,248 (232,365) (261,882) 4,844,758 3,778,012 Reconciliation of net financial assets to net assets Net financial assets as above Non-financial assets and liabilities R & D tax incentive receivable Inventories Prepayments Plant and equipment Intangible assets Accruals Provisions Net assets per Statement of Financial Position The carrying amounts of the Consolidated Entity’s financial assets and financial liabilities are assumed to approximate their fair values due to their short-term nature. ANNUAL REPORT 2018 | Uscom Limited | Page 37 NOTES TO FINANCIAL STATEMENTS Note 22: Related party disclosures Transactions between related parties are on normal commercial terms and conditions, no more favourable than those available to other parties unless otherwise stated. Parent and Controlled Entity Parent Entity Significant investments in subsidiaries: Country of subsidiary incorporation: Proportion of ownership interest: Uscom, Inc. U.S.A 100% Significant investments in subsidiaries: Country of subsidiary incorporation: Proportion of ownership interest: Uscom Medical Ltd U.K. 100% Significant investments in subsidiaries: Country of subsidiary incorporation: Proportion of ownership interest: Thor Laboratories KFT. Hungary 100% Consolidated The Parent and Ultimate Parent Entity is Uscom Limited. Key management personnel The following were key management personnel of the Consolidated Entity at any time during the reporting period and unless otherwise indicated were key management personnel for the entire period: Non-Executive Directors Sheena Jack, Non-Executive Director Christian Bernecker, Non-Executive Director Chao Xiao He, Non-Executive Director (resigned on 23 May 2018) Executive Directors Rob Phillips, Executive Director, Chairman, Chief Executive Officer Senior Executives Nick Schicht, General Manager For further remuneration information of key management personnel refer to the remuneration report in the Directors’ report on pages 9-15. The aggregate compensation made to Directors and other members of key management personnel of the Company and the Consolidated Entity is set out below: Short-term employee benefits Post-employment benefits Share-based payment Total key management personnel remuneration Consolidated 2018 $ 502,325 44,080 134,836 681,241 2017 $ 491,325 54,533 646,730 1,192,588 ANNUAL REPORT 2018 | Uscom Limited | Page 38 NOTES TO FINANCIAL STATEMENTS Note 23: Parent entity information Set out below is the supplementary information about the parent entity. Statement of comprehensive income Loss after income tax Total comprehensive income Statement of financial position Total current assets Total assets Total current liabilities Total liabilities Equity Contributed equity Options reserve Accumulated losses Total equity Parent 2018 $ 2017 $ (1,615,921) (1,615,921) (1,748,666) (1,748,666) 3,778,368 5,323,937 439,131 479,179 2,659,841 4,367,914 596,418 621,970 33,254,701 2,813,371 (31,223,314) 4,844,758 30,332,259 2,708,298 (29,294,613) 3,745,944 Contingent liabilities The parent entity has provided a guarantee in respect of obligations under premises lease of $83,457 (2017: $41,569). No liability was recognised by the parent entity or the consolidated entity in relation to this guarantee. Other than the guarantee mentioned above, the parent entity did not have any contingent liabilities as at 30 June 2018 or 30 June 2017. Significant accounting policies The accounting policies of the parent entity are consistent with those of the consolidated entity, as disclosed in note 2. Note 24: Commitments Operating lease commitments Operating commitments represent payments due for office rentals and have an average term from 18 to 30 months and month to month thereafter. Less than 1 year Between 1 and 5 years Total operating commitments Consolidated 2018 $ 2017 $ 154,100 574,121 728,221 61,035 - 61,035 Lease of assets where substantially all the risks and benefits incidental to the ownership of the asset, but not the legal ownership, are transferred to the Consolidated Entity were classified as finance leases. Finance leases are capitalised, recording an asset and a liability equal to the present value of the minimum lease payments, including any guaranteed residual values. Leased assets are amortised on diminishing value basis over their estimated useful lives where it is likely that the Consolidated Entity will obtain ownership of the asset or over the term of the lease. Lease payments are allocated between the reduction of the lease liability and the lease interest expense for the period. Lease payments for operating leases, where substantially all the risks and benefits remain with the lessor, are recognised as an expense on a straight line basis over the lease term unless another systematic basis is more representative of the time pattern in which benefits are diminished. Lease incentives under operating leases are recognised as liabilities. The incentives are recognised as a reduction of expenses on a straight line basis unless another systematic basis is more representative of the time pattern in which benefits are diminished. ANNUAL REPORT 2018 | Uscom Limited | Page 39 NOTES TO FINANCIAL STATEMENTS Note 25: Auditors’ remuneration a. Audit services BDO East Coast Partnership for Audit and review of financial reports BDO Hungary Audit and review of financial reports Total remuneration for audit services b. Non-audit services BDO East Coast Partnership – other services Total remuneration for Non-audit services Total auditors’ remuneration Consolidated 2018 $ 2017 $ 55,500 10,022 65,522 - - 54,500 7,041 61,541 - - 65,522 61,541 Note 26: Operating segments Segment information The Consolidated Entity operates in the global health and medical products industry. The Consolidated Entity sells two cardiovascular products, the USCOM 1A cardiac output monitor and the Uscom BP+ central blood pressure monitor and a series of pulmonary products the Uscom SpiroSonic spirometers. Globally the Company has five geographic sales and distribution segments Australia, Asia, the Americas, Europe and Mid East and Africa, and other regions. For each segment, the CEO and General Manager review internal management reports on at least a monthly basis. The largest customer group operates in Asia and accounts for 62% of the total sales. For the current period Uscom 1A comprised 75%, SpiroSonic spirometers 20% and BP+ 5% of the total Uscom sales revenue. Basis of accounting for purposes of reporting by operating segments Accounting policies Segment information is prepared in conformity with the accounting policies of the entity as disclosed in note 2 and accounting standard AASB 8 Operating Segments which requires a ‘Management approach’ under which segment information is presented on the same basis as that used for internal reporting purposes. This has resulted in no change to the reportable segments as operating segments continue to be reported in a manner consistent with the internal reporting provided to the chief operating decision maker, which is the Board of Directors. Segment revenues, expenses, assets and liabilities are those that are directly attributable to a segment. Segment assets include all assets used by a segment and consist primarily of inventories, property, plant and equipment and intangible assets. While most of these assets can be directly attributable to individual segments, the carrying amounts of certain assets used jointly by segments are not allocated. Segment liabilities consist primarily of trade and other creditors, employee benefits and provisions for warranties. Segment assets and liabilities do not include deferred income taxes. ANNUAL REPORT 2018 | Uscom Limited | Page 40 NOTES TO FINANCIAL STATEMENTS Note 26: Operating segments (continued) 2018 Sales to external customers Other income Total segment revenue/income Segment expenses Segment result Income tax Consolidated loss from ordinary activities after income tax Australia Asia Americas Europe Other regions Consolidated $ $ $ $ $ $ 63,464 524,206 587,670 3,192,312 (2,604,642) - 1,395,497 - 1,395,497 426,305 969,192 - 34,416 - 34,416 290,433 (256,017) - 573,768 169,451 743,219 861,001 (117,782) (4,628) 100,906 - 100,906 47,952 52,954 - 2,168,051 693,657 2,861,708 4,818,003 (1,956,295) (4,628) (2,604,642) 969,192 (256,017) (122,410) 52,954 (1,960,923) Segment assets Segment liabilities 3,857,282 479,179 99,030 - 572,148 15,450 847,056 36,129 Acquisition of plant and equipment and intangibles Depreciation and amortisation 184,839 50,614 - 13,527 31,059 35,796 42,058 204,366 Australia Asia Americas Europe $ $ $ $ Other regions - - - - $ 5,375,516 530,758 257,956 304,303 Consolidated $ 2017 Sales to external customers Other income Total segment revenue/income Segment expenses Segment result Income tax Consolidated loss from ordinary activities after income tax 47,504 652,300 699,804 3,646,166 (2,946,362) - 1,830,924 - 1,830,924 622,107 1,208,817 - 240,014 - 240,014 411,432 (171,418) - 585,100 123,300 708,400 601,257 107,143 (1,453) 19,817 - 19,817 17,393 2,424 - 2,723,359 775,600 3,498,959 5,298,355 (1,799,396) (1,453) (2,946,362) 1,208,817 (171,418) 105,690 2,424 (1,800,849) Segment assets Segment liabilities 2,540,403 621,970 110,622 - 549,512 7,840 1,285,706 78,421 Acquisition of plant and equipment and intangibles Depreciation and amortisation 69,056 22,022 - 15,363 24,954 37,417 27,286 209,848 - - - - 4,486,243 708,231 121,296 284,650 Note 27: Contingencies Other than the guarantee mentioned at Note 23, the consolidated entity did not have any contingent liabilities as at 30 June 2018 or 30 June 2017. Note 28: Events after the reporting date No matters or circumstances have arisen since the end of the financial year to the date of this report, that has significantly affected or may significantly affect the activities of the Consolidated Entity, the results of those activities or the state of affairs of the Consolidated Entity in the ensuing or any subsequent financial year. ANNUAL REPORT 2018 | Uscom Limited | Page 41 NOTES TO FINANCIAL STATEMENTS DIRECTORS DECLARATION Uscom Limited and its Controlled Entity 1. The directors of the company declare that: The financial statements, comprising the statement of comprehensive income, statement of financial position, statement of cash flows, statement of changes in equity, accompanying notes, are in accordance with the Corporations Act 2001 and: a. comply with Accounting Standards and the Corporations Regulations 2001; and b. give a true and fair view of the consolidated entity’s financial position as at 30 June 2018 and of its performance for the year ended on that date. 2. The company has included in the notes to the financial statements an explicit and unreserved statement of compliance with International Financial Reporting Standards. 3. In the directors’ opinion, there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable. 4. The directors have been given the declarations required by section 295A. This declaration is made in accordance with a resolution of the Board of Directors and is signed for and on behalf of the directors by: Associate Professor Rob Phillips Executive Director - Chairman Sydney, 21 August 2018 ANNUAL REPORT 2018 | Uscom Limited | Page 42 INDEPENDENT AUDIT REPORT Tel: +61 2 9251 4100 Fax: +61 2 9240 9821 www.bdo.com.au Level 11, 1 Margaret St Sydney NSW 2000 Australia INDEPENDENT AUDITOR'S REPORT To the members of Uscom Limited Report on the Audit of the Financial Report Opinion We have audited the financial report of Uscom Limited (the Company) and its subsidiaries (the Group), which comprises the consolidated statement of financial position as at 30 June 2018, the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, and notes to the financial report, including a summary of significant accounting policies and the directors’ declaration. In our opinion the accompanying financial report of the Group, is in accordance with the Corporations Act 2001, including: (i) Giving a true and fair view of the Group’s financial position as at 30 June 2018 and of its financial performance for the year ended on that date; and (ii) Complying with Australian Accounting Standards and the Corporations Regulations 2001. Basis for opinion We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the Audit of the Financial Report section of our report. We are independent of the Group in accordance with the Corporations Act 2001 and the ethical requirements of the Accounting Professional and Ethical Standards Board’s APES 110 Code of Ethics for Professional Accountants (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code. We confirm that the independence declaration required by the Corporations Act 2001, which has been given to the directors of the Company, would be in the same terms if given to the directors as at the time of this auditor’s report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. Key audit matters Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial report of the current period. These matters were addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. BDO East Coast Partnership ABN 83 236 985 726 is a member of a national association of independent entities which are all members of BDO Australia Ltd ABN 77 050 110 275, an Australian company limited by guarantee. BDO East Coast Partnership and BDO Australia Ltd are members of BDO International Ltd, a UK company limited by guarantee, and form part of the international BDO network of independent member firms. Liability limited by a scheme approved under Professional Standards Legislation, other than for the acts or omissions of financial services licensees. ANNUAL REPORT 2018 | Uscom Limited | Page 43 44 INDEPENDENT AUDIT REPORT Impairment and carrying value of intangible assets - Patents and regulatory approvals Key audit matter How the matter was addressed in our audit As disclosed in note 14 of the financial report, the carrying value of the intangibles was considered significant to our audit as the carrying value of Our audit procedures included amongst others: • Performance of a valuation assessment to determine whether the carrying value was $1,154,732 at 30 June 2018 is material to the financial statements and requires considerable judgement and estimation by management based on uncertain outcomes of regulatory approvals. The intangible assets relate to patents held in connection with the BP+ and Uscom 1A products and regulatory approvals of the SpiroThor products which were recognised as part of the acquisition of Thor Laboratories in September • • 2015. impaired. This was done through the assessment of estimated future discounted cash flows. Verified movements in the carrying value of intangibles. Scrutinised the inputs of the forecasts provided by management and agreed to supporting documentation, such as historical data and distribution agreements, where appropriate. • Reviewed the status of regulatory submissions when assessing any potential impairment indicators. Other information The directors are responsible for the other information. The other information comprises the information in the Group’s annual report for the year ended 30 June 2018, but does not include the financial report and the auditor’s report thereon. Our opinion on the financial report does not cover the other information and we do not express any form of assurance conclusion thereon. In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard. Responsibilities of the directors for the Financial Report The directors of the Company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001 and for such internal control as the directors determine is necessary to enable the preparation of the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error. ANNUAL REPORT 2018 | Uscom Limited | Page 44 INDEPENDENT AUDIT REPORT In preparing the financial report, the directors are responsible for assessing the ability of the group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or has no realistic alternative but to do so. Auditor’s responsibilities for the audit of the Financial Report Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report. A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website (http://www.auasb.gov.au/Home.aspx) at: http://www.auasb.gov.au/auditors_responsibilities/ar1.pdf This description forms part of our auditor’s report. Report on the Remuneration Report Opinion on the Remuneration Report We have audited the Remuneration Report included in the directors’ report for the year ended 30 June 2018. In our opinion, the Remuneration Report of Uscom Limited, for the year ended 30 June 2018, complies with section 300A of the Corporations Act 2001. Responsibilities The directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the Corporations Act 2001. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards. BDO East Coast Partnership Gareth Few Partner Sydney, 21 August 2018 ANNUAL REPORT 2018 | Uscom Limited | Page 45 SHAREHOLDER INFORMATION SHAREHOLDER INFORMATION Additional information required by Australian Stock Exchange Listing Rules is as follows. This information is current as at 31 July 2018. (a) Distribution Schedules of Shareholder Holdings Ranges Holders Ordinary shares 1 – 1,000 1,001 – 5,000 5,001 – 10,000 10,001 – 100,000 100,001 – 99,999,999,999 Total Number 113 183 87 299 141 823 Number 67,716 551,580 700,500 11,785,595 124,153,981 137,259,372 % 0.05% 0.40% 0.51% 8.59% 90.45% 100% There were 211 holders of less than a marketable parcel of 2,942 ordinary shares. (b) Class of shares and voting rights All shares are ordinary shares. Each ordinary share is entitled to one vote when a poll is called, otherwise each member present at a meeting or by proxy has one vote on a show of hands. Substantial shareholders (c) The names of the substantial shareholders listed in the holding company’s register as at 31 July 2018 are: DR ROBERT ALLAN PHILLIPS DR STEPHEN FREDERICK WOODFORD HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED - A/C 2 MR JOHN LIONEL GLEESON JETAN PTY LTD (d) Twenty largest registered holders – ordinary shares Balance as at 31 July 2018 CITICORP NOMINEES PTY LIMITED MR ROBERT ALLAN PHILLIPS HSBC CUSTODY NOMINEES J P MORGAN NOMINEES AUSTRALIA MR JOHN LIONEL GLEESON JETAN PTY LTD DONGJUN SUN DRP CARTONS (NSW) PTY LTD NETWEALTH INVESTMENTS LIMITED BELL POTTER NOMINEES LTD CORF CORPORATION PTY LIMITED INVIA CUSTODIAN PTY LIMITED EASTBOURNE ROAD PTY LTD NETWEALTH INVESTMENTS LIMITED DULYNE PTY LTD RAEWYN JANETTE LOVETT & MR CHRISTOPHER JAMES WERE & DR RUSSELL KAY HANCOCK QUERION PTY LTD MR DAVID LEROY BOYLES Total ANNUAL REPORT 2018 | Uscom Limited | Page 46 21,352,794 10,258,475 6,266,609 3,100,000 3,050,000 Ordinary shares Number 23,624,762 23,501,158 6,266,609 3,899,487 3,503,863 3,200,000 2,414,125 2,359,616 2,131,412 2,116,636 2,104,500 2,088,118 1,830,904 1,568,992 1,550,000 1,477,640 1,424,095 1,400,000 1,266,667 1,250,000 % 17.212% 17.122% 4.566% 2.841% 2.553% 2.331% 1.759% 1.719% 1.553% 1.542% 1.533% 1.521% 1.334% 1.143% 1.129% 1.077% 1.038% 1.020% 0.923% 0.911% 88,978,584 64.825% SHAREHOLDER INFORMATION Registered office and principal place of office Level 8, Suite 2, 66 Clarence Street Sydney NSW 2000 Australia Tel: Fax: 02 9247 4144 02 9247 8157 Company Secretary Brett Crowley Registers of securities Boardroom Pty Limited Level 12, 225 George Street Sydney NSW 2000 Australia GPO Box 3993 Sydney NSW 2001 Australia 1300 737 760 Tel: Fax: 1300 653 459 www.boardroomlimited.com.au Stock exchange listing Quotation has been granted for 137,259,372 ordinary shares of the Company as at 31 July 2018 on all Member Exchanges of the Australian Stock Exchange Limited. Unquoted securities Rights over unissued shares as at 31 July 2018 A total of 450,000 rights over ordinary shares are on issue to an executive under the new Equity Incentive Plan. ANNUAL REPORT 2018 | Uscom Limited | Page 47 

Continue reading text version or see original annual report in PDF format above